Syndax Pharmaceuticals, Inc.
SNDX
$16.24
$0.402.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 42.70% | 160.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 89.39% | 160.96% | |||
| Cost of Revenue | 7,075.82% | -98.67% | |||
| Gross Profit | -233.36% | 132.65% | |||
| SG&A Expenses | 6.76% | 8.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.63% | -0.47% | |||
| Operating Income | 16.95% | 13.34% | |||
| Income Before Tax | 15.32% | 9.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 15.32% | 9.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.32% | 9.90% | |||
| EBIT | 16.95% | 13.34% | |||
| EBITDA | 16.95% | 13.34% | |||
| EPS Basic | 15.48% | 10.30% | |||
| Normalized Basic EPS | 15.49% | 10.29% | |||
| EPS Diluted | 15.48% | 10.30% | |||
| Normalized Diluted EPS | 15.49% | 10.29% | |||
| Average Basic Shares Outstanding | 0.19% | 0.44% | |||
| Average Diluted Shares Outstanding | 0.19% | 0.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||